Stock Detail
Videos
ChromaDex Corporation (CDXC) Fireside Chat
During this fireside chat Ben Shamsian, Vice President, Lytham Partners and Sean McGowan, Roth Capital Partners, chat with Rob Fried, Chief Executive Officer of ChromaDex Corporation. ChromaDex (NASDAQ:CDXC) is the global authority on nicotinamide adenine dinucleotide...
News
ChromaDex to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
LOS ANGELES - ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, today announced that it will participate in a webcasted company presentation at the Lytham Partners 2025...
ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) proudly announces its inclusion on the Inc. 2024 Best in Business list in the Health Products category. Inc.'s annual Best in Business Awards celebrate the exceptional achievements and contributions of companies that have...
ChromaDex’s Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology’s Inaugural Longevity Supplement
The gold standard in NAD+ supplementation, Niagen® is a key ingredient for supporting cellular health and promoting healthy aging in Longevity.Technology's new supplement LOS ANGELES - ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine...